Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a wearable headband quiet the Brain's OCD circuitry?

NCT ID NCT07728994

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a wearable headband called ATTN201 can safely reduce obsessive-compulsive disorder (OCD) symptoms. The device delivers low-intensity focused ultrasound to a deep brain region involved in OCD, without surgery. Forty adults with moderate-to-severe OCD will receive either active or sham stimulation over several weeks to see if the treatment eases symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a wearable headband that delivers low-intensity focused ultrasound to the subthalamic nucleus
What this could lead to
If it works, this could offer a non-invasive, drug-free option for people with OCD who do not respond well to standard treatments.
What could go wrong
This is an early-stage trial with only 40 participants, so results may not apply to everyone. The device is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have a principal diagnosis of OCD according to the DSM-5 with duration of \> 1 year 2. Have a Y-BOCS of \> 16 3. Participants currently on OCD medication must be at the same stable dose(s) for at least 3 weeks prior to screening and throughout the course of the study, and must continue to be under the care of their treating psychiatrist through the duration of the study. 4. Be between 22 to 80 years of age (inclusive) on the day of signing informed consent. 5. Be able and willing to undergo a cranial MRI 6. Be able and willing to wear an Attune device throughout the experimental sessions. 7. Sign the informed consent form, in accordance with local requirements, after the scope and nature of the investigation have been explained to the subject, and before screening assessments. 8. Be able to speak, read, and understand the language of the trial staff and the informed consent form. 9. Possess the ability to respond verbally to questions, follow instructions, and complete study assessments. 10. Be able to adhere to the stimulation protocol and visit schedules. 11. Be determined by the investigator to be medically stable at baseline/randomization as assessed by medical history and non-significant clinical results of a vital signs examination. 12. Male participants must ensure a condom is used for all sexual intercourse and follow acceptable methods of contraception for their female partner for the entire duration of the study. Male participants should not father a child or donate sperm for this same period. 13. Female participants who are sexually active agree to use two methods of contraception for the duration of the study or not be of childbearing potential as indicated by one of the following: 1. Has reached natural menopause, defined as 45 years of age with ≥6 months of spontaneous amenorrhea 2. Has had a hysterectomy; 3. Has had bilateral tubal ligation; or 4. Has had a bilateral oophorectomy (with or without a hysterectomy) and greater than 6 weeks have passed since the surgery Exclusion Criteria: 1. Has a current or prior history of bipolar I or II disorder, schizophrenia or other psychotic disorder, borderline personality disorder, Tourette's disorder 2. Has acute suicidality or suicide attempt or self-injurious behavior in the last 6 months 3. Has a history of deep brain stimulation or ablative surgery 4. Has a history of substance abuse including alcohol use disorder in the past 6 months (except for caffeine and nicotine) 5. Has a history of traumatic brain injury with loss of consciousness, seizures,or other neurological disorders. 6. Has any contraindications for completing a brain MRI scan. a. The subject's head must fit within the head coil (32 or 64 channel), while wearing the MR-compatible device. 7. Has had a ketamine or TMS treatment within the last month prior to recruitment. 8. Has had any medical or psychiatric symptoms or conditions that could interfere with study activities or confound interpretation of study results. 9. Has a recent or ongoing, uncontrolled, clinically significant medical condition where participation in the trial would pose a significant medical risk to the subject or would confound study results within 3 months of Screening, such as: 1. Conditions including but not limited to diabetes, hypertension, Human Immunodeficiency Virus (HIV) or other relevant infections, thyroid or endocrine disease, Chronic Obstructive Pulmonary Disease (COPD), delirium, congestive heart failure, angina, cardiac or gastrointestinal disease, or renal disease requiring dialysis, or unstable malignancies. 2. Major surgery including not limited to abdominal, thoracic, cardiac, or orthopedic surgery, or any procedure requiring general anesthesia. 3. Subjects with recently controlled or treated medical conditions may be considered for re-screening on a case-by-case basis after consultation with the Sponsor. 4. Has a history of hepatitis or liver disease that, in the opinion of the investigator, has been active within the 6 months prior to Visit 1. 10. Is pregnant, is attempting to become pregnant, or is nursing children. 11. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an investigational site or sponsor staff directly involved with this trial. 12. Has a Body Mass Index (BMI) \>34 kg/m2. BMI is calculated by taking the subject's weight in kg and dividing by the subject's height in meters, squared

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obsessive compulsive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Attune Neurosciences

    RECRUITING

    San Francisco, California, 94107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.